Saturday, July 11, 2026

Drug profile · INN

sulfinpyrazone

sulfinpyrazone (SULFINPYRAZONE) is a solute carrier family 22 member 12 inhibitor. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — sulfinpyrazone
US status
approved
Class
Route
ORAL
Patents
0
Programs
0
Data quality
0.84

Quick answer

sulfinpyrazone (SULFINPYRAZONE) is a solute carrier family 22 member 12 inhibitor. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN sulfinpyrazone
Brand SULFINPYRAZONE
Mechanism Solute carrier family 22 member 12 inhibitor
Target Solute carrier family 22 member 12
Route ORAL
Formulation CAPSULE

Mechanism of action

Solute carrier family 22 member 12 inhibitor

Primary target: Solute carrier family 22 member 12

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. lesinurad Musculo-skeletal system (M04)

Frequently asked questions

What is sulfinpyrazone?

sulfinpyrazone (SULFINPYRAZONE) is a solute carrier family 22 member 12 inhibitor. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for sulfinpyrazone?

SULFINPYRAZONE is a marketed brand name for sulfinpyrazone. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of sulfinpyrazone?

sulfinpyrazone has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.